Sanofi, a global healthcare leader headquartered in France, is renowned for its commitment to improving health and well-being. Founded in 2004 through the merger of Sanofi-Synthélabo and Aventis, the company has established a strong presence in key operational regions, including Europe, North America, and Asia. Operating within the pharmaceutical and biotechnology industry, Sanofi focuses on several main business areas, including prescription medicines, vaccines, and consumer healthcare products. Its core offerings, such as innovative treatments for diabetes, rare diseases, and vaccines, are distinguished by their scientific rigor and patient-centric approach. With a robust market position, Sanofi has achieved notable milestones, including advancements in immunology and oncology, solidifying its reputation as a trusted name in global health solutions.
How does Sanofi's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sanofi's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Sanofi reported total greenhouse gas emissions of approximately 4,196,976,000 kg CO2e, with Scope 1 emissions at about 298,485,000 kg CO2e, Scope 2 emissions at approximately 75,864,000 kg CO2e (market-based), and a significant Scope 3 contribution of around 3,822,627,000 kg CO2e. This reflects a slight decrease from 2023, where total emissions were about 4,448,234,000 kg CO2e, with Scope 1 at approximately 332,470,000 kg CO2e, Scope 2 at about 90,752,000 kg CO2e (market-based), and Scope 3 at around 4,025,012,000 kg CO2e. Sanofi has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 55% by 2030, using a 2019 baseline. Additionally, the company targets a 30% reduction in absolute Scope 3 emissions by the same year. Long-term goals include achieving net-zero greenhouse gas emissions across its value chain by 2045, with a 90% reduction in emissions from all scopes by that date. Sanofi's commitment to sustainability is validated by the Science Based Targets initiative (SBTi), which has approved these targets as consistent with limiting global warming to 1.5°C. The company also plans to increase its sourcing of renewable electricity from 11% in 2019 to 100% by 2030, further enhancing its climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sanofi is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.